Immunosuppressants and antifibrotics are currently used to treat patients with various
interstitial lung diseases, which may undergo lung transplantation (LTx). The retrospective …

Antifibrotic treatment has been approved for reducing disease progression in fibrotic
interstitial lung disease (ILD). As a result of increased bleeding risk, some experts suggest …

Background Previous studies have reported similarities in long-term outcomes following
lung transplantation for connective tissue disease-associated interstitial lung disease (CTD …

Background Idiopathic pulmonary fibrosis (IPF) is a rapidly progressive interstitial lung
disease with high mortality. Lung transplant remains a cornerstone of treatment despite the …

Background Anti-fibrotic drugs may interfere with wound-healing after major surgery,
theoretically preventing sufficient bronchial anastomosis formation after lung transplantation …

A best evidence topic was written according to a structured protocol. The question
addressed was:'Does continuation of antifibrotics before lung transplantation (LTx) influence …

Background Acute exacerbation of interstitial lung disease (AE-ILD) significantly impacts
prognosis, leading to high mortality rates. Although lung transplantation is a life-saving …

Purpose Pirfenidone and nintedanib are antifibrotic agents that have been shown to slow
the progression of Idiopathic Pulmonary Fibrosis (IPF). Since FDA approval in 2014, many …

Lung transplantation (LTx) can be a life-extending treatment option for patients with
advanced and/or progressive fibrotic interstitial lung disease (ILD), especially idiopathic …

Background and objective Antifibrotic drugs are the standard treatments for patients with
idiopathic pulmonary fibrosis (IPF). This study aims to assess the safety of antifibrotic …